Company intelligence / Profile preview
Enterprise Therapeutics
Brighton/Sussex area & London Blackfriars offices, England, United Kingdomenterprisetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ETD001, the company's lead compound targeting ENaC for cystic fibrosis and other respiratory diseases, entered Phase 2 trials in early 2024. The program has also received rare pediatric disease designation from the FDA in September 2024. The approach aims to be mutation agnostic and disease-modifying by improving airway hydration and mucus clearance. No published late-stage results yet.
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Backed by top-tier venture capital investors including Novartis Venture Fund, Versant Ventures, Forbion, IP Group Life Sciences Investment Team, Panakes Partners.
Beyond the preview
Go deeper on Enterprise Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enterprise Therapeutics.